BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38583049)

  • 21. Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma.
    Bayley JP; Bausch B; Rijken JA; van Hulsteijn LT; Jansen JC; Ascher D; Pires DEV; Hes FJ; Hensen EF; Corssmit EPM; Devilee P; Neumann HPH
    J Med Genet; 2020 Feb; 57(2):96-103. PubMed ID: 31492822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
    Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
    Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
    Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
    Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
    Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Properly Collected Plasma Metanephrines Excludes PPGL After False-Positive Screening Tests.
    Kline GA; Boyd J; Polzin B; Harvey A; Pasieka JL; Sadrzadeh HSM; Leung AA
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2900-e2906. PubMed ID: 33846745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea.
    Park H; Kim MS; Lee J; Kim JH; Jeong BC; Lee S; Lee SK; Cho SY; Jin DK
    Front Endocrinol (Lausanne); 2020; 11():610746. PubMed ID: 33584544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.
    de Cubas AA; Korpershoek E; Inglada-Pérez L; Letouzé E; Currás-Freixes M; Fernández AF; Comino-Méndez I; Schiavi F; Mancikova V; Eisenhofer G; Mannelli M; Opocher G; Timmers H; Beuschlein F; de Krijger R; Cascon A; Rodríguez-Antona C; Fraga MF; Favier J; Gimenez-Roqueplo AP; Robledo M
    Clin Cancer Res; 2015 Jul; 21(13):3020-30. PubMed ID: 25825477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma.
    Jafri M; Whitworth J; Rattenberry E; Vialard L; Kilby G; Kumar AV; Izatt L; Lalloo F; Brennan P; Cook J; Morrison PJ; Canham N; Armstrong R; Brewer C; Tomkins S; Donaldson A; Barwell J; Cole TR; Atkinson AB; Aylwin S; Ball SG; Srirangalingam U; Chew SL; Evans DG; Hodgson SV; Irving R; Woodward E; Macdonald F; Maher ER
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):898-906. PubMed ID: 23072324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline
    Alzahrani AS; Bin Nafisah A; Alswailem M; Moria Y; Poprawski D; Al-Hindi H; Pacak K
    Front Endocrinol (Lausanne); 2023; 14():1273093. PubMed ID: 38152133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic and clinical aspects of paediatric pheochromocytomas and paragangliomas.
    Petenuci J; Guimaraes AG; Fagundes GFC; Benedetti AFF; Afonso ACF; Pereira MAA; Zerbini MCN; Siqueira S; Yamauchi F; Soares SC; Srougi V; Tanno FY; Chambo JL; Lopes RI; Denes FT; Hoff AO; Latronico AC; Mendonca BB; Fragoso MCBV; Almeida MQ
    Clin Endocrinol (Oxf); 2021 Jul; 95(1):117-124. PubMed ID: 33745191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield.
    Horton C; LaDuca H; Deckman A; Durda K; Jackson M; Richardson ME; Tian Y; Yussuf A; Jasperson K; Else T
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e1917-e1923. PubMed ID: 35026032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Bayley JP; Bausch B; Jansen JC; Hensen EF; van der Tuin K; Corssmit EP; Devilee P; Neumann HP
    J Med Genet; 2023 Jan; 60(1):25-32. PubMed ID: 34750193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
    van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN
    Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
    Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
    J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
    Li M; Prodanov T; Meuter L; Kerstens MN; Bechmann N; Prejbisz A; Remde H; Timmers HJLM; Nölting S; Talvacchio S; Berends AMA; Fliedner S; Robledo M; Lenders JWM; Pacak K; Eisenhofer G; Pamporaki C
    J Clin Endocrinol Metab; 2023 Jan; 108(2):397-404. PubMed ID: 36190922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.